Article
KAT7 is a therapeutic vulnerability of MLL-rearranged acute myeloid leukemia
medRxiv · 2020 · Au, Y. Z.; Gu, M.; De Braekeleer, E.; Yu, J. S. L.; Ong, S. H.; Gozdecka, M.; Chen, X.; Tzelepis, K.; Huntly, B. J. P.; Vassiliou, G. S.; Yusa, K.
Key facts
| Title | KAT7 is a therapeutic vulnerability of MLL-rearranged acute myeloid leukemia |
|---|---|
| First author | Au, Y. Z.; Gu, M.; De Braekeleer, E.; Yu, J. S. L.; Ong, S. H.; Gozdecka, M.; Chen, X.; Tzelepis, K.; Huntly, B. J. P.; Vassiliou, G. S.; Yusa, K. |
| Journal | medRxiv |
| Published | Apr 25, 2020 |
| DOI | 10.1101/2020.04.25.054049 |
| Devices mentioned | BK110039 |
| Product codes mentioned | JJH, JJX, KIT, MVU, NDS, NJT, PFT, PCA |
At a glance
- 1–9 FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1